Research and Markets (http://www.researchandmarkets.com/research/420ecc/competitor_analysi) has announced the addition of the "Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)" report to their offering.
The Competitive Intelligence Report FSH, hCG and LH: Therapeutic Proteins for Assisted Reproductive Technology (ART) as of November 2009 provides a competitor analysis in the development pipeline of novel recombinant, transgenic and oral FSH, hCG and LH receptor agonists for treatment of infertility.
Follicle-stimulating hormone (FSH) now has become an established means of ovulation induction (OI) as part of assisted reproductive technology (ART). FSH is used to induce development of multiple follicles in ovulatory women and anovulatory infertile women. The major recombinant FSH products posted 2008 sales of US$ 1.25 bln. Current recombinant (follitropin) as well as highly purified human urinary (urofollitropin) FSH preparations have replaced earlier products with painful IM administrations. Current focus of new development lies on longer-acting and needle-free preparations. The most advanced projects are in registration or late clinical development. Other innovations in FSH R&D are modern production technologies in new expression systems such as plants or transgenic animals. The search for more effective FSH is ongoing and oral FSH receptor agonists have been identified.
Luteinizing Hormone (LH) is being used as part of menotropin preparations together with FSH or alone if profound LH deficiency has been diagnosed. Human choriogonadotropin or chorionic gonadotropin (hCG) aids in final maturation of the eggs and triggers ovulation.
The report describes the market size of major FSH products, provides information on the marketed FSH, hCG and LH preparations and includes a compilation of current active projects in research and development of novel FSH, LH and hCG receptor agonists.
Competitor projects are listed in a tabular format providing information on: